At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 24 enrolled
Drug / intervention
Ivermectin +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomised, Double-Blind, Placebo-Controlled, Exploratory Phase I Trial Assessing the Pharmacokinetic Profile, Safety and Tolerability of a Continuous Daily Dosing Regimen of Active IMP in Healthy Volunteers
In Brief
A Phase 1 clinical trial evaluating Ivermectin and Placebo for Covid19. Completed, enrolled 24 participants across 1 site.
Detailed Summary
An early stage trial to check how safe and tolerable, as well as how the body handles continuous daily use of Active IMP over 28 days in healthy volunteers.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCovid19
CountriesUnited Kingdom
Collaborators--
Timeline
Phase 1CompletedFinished
202120222023202420252026
Enrollment StartSep 2020
First PostedNov 2020
Primary CompletionMar 2021
TodayJul 2026
First PostedNov 17, 2020
Enrollment StartSep 22, 2020
Primary CompletionMar 9, 2021
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 5.6 years ago
Interventions
Ivermectindrug
Ivermectin: Investigation of the safety, tolerability and the pharmacokinetic profile of the active IMP in an exploratory study
Placebodrug
Matching Placebo to the Active IMP.